Synlogic CapEx/OCF

What does Synlogic do? Synlogic, Inc. develops synthetic biotic medicines using its proprietary Synthetic Biotic platform to treat rare genetic diseases such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). The company focuses on inborn errors of metabolism (IEM) and other conditions including inflammatory bowel disease, cancer, and metabolic disorders like diabetes and obesity. SYNB1020 targets UCD and hepatic encephalopathy (HE), while SYNB1618 is designed for PKU treatment. The firm operates as a clinical-stage biopharmaceutical company with a pipeline centered on genetically reengineered probiotics that perform missing or damaged functions due to disease. Synlogic's revenue model is based on developing and advancing clinical-stage therapies for rare and complex conditions. The company's pipeline includes SYNB1020 and SYNB1618, which are in development for specific disease indications. As a clinical-stage biopharmaceutical firm, Synlogic generates value through the progression of its drug candidates toward regulatory approval and potential commercialization. The company's focus on rare genetic diseases and metabolic conditions positions it to address unmet medical needs in specialized therapeutic areas. Synlogic targets patients with rare genetic disorders such as UCD and PKU, as well as those suffering from inflammatory bowel disease, cancer, and metabolic conditions including diabetes and obesity. The company's synthetic biotic approach aims to provide novel therapeutic solutions where traditional treatments may be insufficient. By leveraging synthetic biology to reengineer probiotics, Synlogic addresses critical medical gaps in the treatment of these complex conditions, focusing on both rare and broader metabolic disease markets. Synlogic is one of the most popular companies on Eulerpool.